Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

24-07-22	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
21-12-09	TearLab Corporation Announces Board Appointments	CI
21-12-09	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	CI
21-11-09	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	CI
21-09-16	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	CI
20-07-28	TearLab Appoints Adam Szaronos as Chief Commercial Officer	CI
20-07-08	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	CI
20-07-08	TearLab Corporation to Seek Acquisitions	CI
20-06-26	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
20-05-11	TearLab Corporation Announces Board Appointments	CI
20-05-11	Tearlab Mulls Inorganic Growth Opportunities	CI
20-05-10	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	CI
20-05-10	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	CI

20-07-09	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-06-26	TearLab: 1Q Earnings Snapshot	AQ
20-06-26	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
20-06-08	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	AQ
20-05-29	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	AQ

Manager	Title	Age	Since
Adam Szaronos CEO	Chief Executive Officer	-	2026-03-31
Benjamin Sullivan CTO	Chief Tech/Sci/R&D Officer	-	2009-07-16
John Lund DFI	Director of Finance/CFO	60	2022-06-30

Director	Title	Age	Since
Uri Geiger BRD	Director/Board Member	58	2020-07-08
James V. Mazzo CHM	Chairman	68	2021-12-08
Richard Lindstrom BRD	Director/Board Member	78	2004-08-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/9/20	Joseph S. Jensen	Tender	Chief Executive Officer	29,206	0.1196%
7/9/20	Michael Marquez	Tender	Chief Financial Officer	500	0.0020%
7/9/20	Paul M. Karpecki	Tender	Director	102,200	0.4187%

TearLab Corporation Stock

Stocks

Medical Equipment, Supplies & Distribution

Latest news : TearLab Corporation

Press Releases : TearLab Corporation

Managers and Directors : TearLab Corporation

Latest insider transactions

Glasses, Spectacles & Contact Lenses

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TEARLAB CORPORATION	-.--%	+2.84%	-	-	1.41M
ESSILORLUXOTTICA	+2.44%	-1.13%	-38.74%	-8.39%	84.33B
ALCON INC.	-0.96%	-1.53%	-9.19%	-21.93%	35.16B
THE COOPER COMPANIES, INC.	+0.53%	-6.45%	+10.41%	-23.61%	13.84B
LENSKART SOLUTIONS LIMITED	-0.69%	-2.85%	-	-	11.66B
SHANGHAI CONANT OPTICAL CO., LTD.	+3.08%	+15.25%	-5.76%	+760.11%	2.73B
AUTEK CHINA INC.	-0.81%	-3.61%	-40.50%	-56.92%	1.47B
PEGAVISION CORPORATION	+0.53%	+0.80%	+18.74%	+12.04%	909M
SPYGLASS PHARMA, INC.	-2.69%	-1.26%	-	-	901M
MINGYUE OPTICAL LENS CO.,LTD.	-1.45%	-1.25%	-39.87%	-14.29%	887M
Average	+0.10%	+1.40%	-14.99%	+92.43%	16.88B
Weighted average by Cap.	+1.38%	-1.95%	-25.41%	+1.30%